Deals
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space
CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, to be held at the Ritz-Carlton here. The 2019 program will cover late-breaking clinical data, corporate strategies, and financial insights from a dynamic mix of private and public companies and…
Read MoreOIS Index Posts Modest Gain for Q2; Ophthalmic Market Leader Alcon Joins Index
The OIS Index of ophthalmic stocks posted a modest positive return of +0.8% during the second quarter of 2019. The index outperformed the NASDAQ Biotechnology Index (–2.4%) but lagged the overall US stock market as measured by the Russell 3000 Index (+4.3%) and a composite of US medical device stocks (+4%). Declining stocks in the…
Read MoreA Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In
NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63 billion. Reaction from the investor community was deeply mixed. The announcement on Tuesday set off the worst day for AbbVie’s stock since it was spun off from its parent company,…
Read MoreWhy Equity and M&A Markets in Ophthalmology Are Poised for a Great Run
SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is a continued strong year, according to J.P. Peltier, managing director, global head, healthcare investment banking at Piper Jaffray. Peltier gave his overview of the equity and M&A markets in ophthalmology…
Read MoreA Dozen Takeaways from OIS@ASCRS 2019
Last week’s OIS@ASCRS 2019 saw a record number of registrants, and the 650 attendees were treated to a wealth of information from the presenting companies, many on the dais for the first time at an Ophthalmology Innovation Summit. Here’s an even dozen takeaways. Vicken Karageozian, MD, president and CEO of Allegro Ophthalmics, gave a preview…
Read MoreOIS@ASCRS Features New Sessions, Companies
OIS@ASCRS 2019 will convene next Thursday, May 2, preceding the American Society of Cataract and Refractive Surgery annual meeting in San Diego. This year’s OIS@ASCRS features a few new additions, as OIS co-founder and Healthegy CEO Craig Simak points out. These include a switch from the “Masters of the Industry” session to “The Emerging Leaders…
Read MoreOIS Index Delivers Stellar First-Quarter 2019 Performance
The OIS Index of ophthalmic stocks solidly outperformed its market benchmarks in the first quarter of 2019, gaining 37.1%. During Q1, the overall US stock market, as measured by the Russell 3000 Index, gained 12.8%. The NASDAQ Biotechnology Index gained 15.4%, and a composite of US medical device stocks gained 15.9%. For the OIS Index,…
Read MoreBiogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition
It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic Technologies Corp. Last week, about 11 weeks after nixing the AGTC deal, Biogen entered into an agreement to acquire another clinical-stage gene therapy company with promising programs in ophthalmology, Nightstar…
Read MoreHow Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’
SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device companies, described the “early Death Valley” that panel participants know all too well. To get beyond Death Valley, medical device companies have to think creatively. Here’s how some of those…
Read More10 Takeaways from Roche’s $4.8 Billion Offer to Acquire Spark Therapeutics
Here are 10 things to know about Roche’s $4.8 billion bid to acquire Spark Therapeutics. Roche’s $114.5-a-share offer is a 122% premium over the closing price of Spark’s stock ($51.54) on February 22. On the day the offer was announced, Spark’s shares shot up to $113.48. In 2018, Spark shipped 75 vials of $425,000-per-eye Luxturna…
Read MoreCorporate Leaders Explain the Upside of the Optometric Channel
NEW ORLEANS – Optometry has become a source of big business for ophthalmic companies over the past decade, with about 40 to 60% of sales coming from optometric channels, industry leaders said here last week in a panel discussion at OIS@SECO 2019. Allergan has spent the last 10 years focused on partnering with optometry and…
Read MoreOIS Index Follows the Stock Market Lower in December
The OIS Index declined 11% in December, marking the fourth month in a row in which ophthalmic stocks lost value. For the month, the overall US stock market as measured by the Russell 3000 Index declined 9.5% and the NASDAQ Biotechnology Index 11.3%. A composite of US medical device stocks slightly outperformed the other benchmarks,…
Read More